Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
Rini, B. I. Plimack, E. R. Stus, V. Gafanov, R. Waddell, Thomas Nosov, D. Pouliot, F. Alekseev, B. Soulieres, D. Melichar, B.
Rini, B. I.
Plimack, E. R.
Stus, V.
Gafanov, R.
Waddell, Thomas
Nosov, D.
Pouliot, F.
Alekseev, B.
Soulieres, D.
Melichar, B.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Rini BI, Plimack ER, Stus V, Gafanov R, Waddell T, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. Journal of Clinical Oncology. 2023 Jun;41(17). PubMed PMID: WOS:001043181100025.